After Haleon spinoff, GSK raises forecasts on ‘strong’ Q3

In its first set of quarterly results since it separated from its consumer health business, GSK has exceeded analysts’ estimates, with a healthy rise in revenue and profit driven by shingles vaccine Shingrix.